Dr. Mark McPike, CEO of AptaMatrix* and CNYBAC client, is an NIH-SBIR-STTR grant reviewer and has submitted close to 50 NIH SBIR-STTR grants to-date. He will address issues for applicants – in time for the NIH April 5th deadline.
Bring your SBIR/STTR questions to this virtual Q&A Meetup.
*AptaMatrix is a Syracuse-based biotech company focused on developing aptamer-based technologies for diagnostic applications, announces that it has been awarded a $2M Phase II Small Business Innovation Research (SBIR) grant by the National Institute of General Medical Sciences (NIGMS) institute of the National Institutes of Health (NIH). The Phase II award will allow AptaMatrix to develop and optimize their novel, aptamer-based, plasma proteome assay designed to operate on existing high throughput DNA sequencing systems. This assay aims to provide deep analysis of the human plasma proteome for detection and characterization of novel prostate cancer biomarkers. If successful, clinical and research laboratories could use this assay to diagnose cancer and monitor the progress of treatment. If successful, the AP3 - Assay will be expanded for detection of other diseases beyond cancer.
